Burns – Pipeline Review, H1 2016

$2,000

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research…..

Total Pages: 107

Global Markets Direct’s, ‘Burns - Pipeline Review, H1 2016’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Burns
- The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burns therapeutics and enlists all their major and minor projects
- The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burns

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burns
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Burns Overview 10
Therapeutics Development 11
Pipeline Products for Burns - Overview 11
Pipeline Products for Burns - Comparative Analysis 12
Burns - Therapeutics under Development by Companies 13
Burns - Therapeutics under Investigation by Universities/Institutes 15
Burns - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Burns - Products under Development by Companies 20
Burns - Products under Investigation by Universities/Institutes 22
Burns - Companies Involved in Therapeutics Development 23
Adocia 23
AlgiPharma AS 24
Amarantus Bioscience Holdings, Inc. 25
American Gene Technologies International Inc. 26
Biogenomics Limited 27
CytoTools AG 28
Destiny Pharma Limited 29
HanAll Biopharma Co., Ltd. 30
Kuros Biosciences AG 31
Madam Therapeutics B.V. 32
MediWound Ltd. 33
Novartis AG 34
Phosphagenics Limited 35
Se-cure Pharmaceuticals Ltd. 36
Stratatech Corporation 37
USV Limited 38
Burns - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
A-3APO - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AG-110 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
albumin (human) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ALLO-ASC - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Biochaperone PDGF-BB - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
bromelains - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BVS-857 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy for Dermatology and Immunology - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
epidermal growth factor biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Gene Therapy for Burns - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
HL-156FIB - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
IMSP-001 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
KUR-212 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
lidocaine hydrochloride - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibody Conjugate to Target TNF-alpha for Burns and Wounds - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MP-101 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Neu-2000 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Nu-2 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Oligomer G for Wounds And Burns - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
P-12 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
P-148 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PEP-04 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SC-106 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
silver sulfadiazine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules for Burn - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
XF-70 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Burns - Recent Pipeline Updates 86
Burns - Dormant Projects 90
Burns - Discontinued Products 93
Burns - Product Development Milestones 94
Featured News & Press Releases 94
Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized 94
Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS) 95
Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters 95
Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania 96
Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid 97
Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S. 98
Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress 99
Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress 100
Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting 104
Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 106
Disclaimer 107

List of Tables
Number of Products under Development for Burns, H1 2016 11
Number of Products under Development for Burns - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Comparative Analysis by Unknown Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Burns - Pipeline by Adocia, H1 2016 23
Burns - Pipeline by AlgiPharma AS, H1 2016 24
Burns - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 25
Burns - Pipeline by American Gene Technologies International Inc., H1 2016 26
Burns - Pipeline by Biogenomics Limited, H1 2016 27
Burns - Pipeline by CytoTools AG, H1 2016 28
Burns - Pipeline by Destiny Pharma Limited, H1 2016 29
Burns - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 30
Burns - Pipeline by Kuros Biosciences AG, H1 2016 31
Burns - Pipeline by Madam Therapeutics B.V., H1 2016 32
Burns - Pipeline by MediWound Ltd., H1 2016 33
Burns - Pipeline by Novartis AG, H1 2016 34
Burns - Pipeline by Phosphagenics Limited, H1 2016 35
Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H1 2016 36
Burns - Pipeline by Stratatech Corporation, H1 2016 37
Burns - Pipeline by USV Limited, H1 2016 38
Assessment by Monotherapy Products, H1 2016 39
Assessment by Combination Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 44
Number of Products by Stage and Route of Administration, H1 2016 46
Number of Products by Stage and Molecule Type, H1 2016 48
Burns Therapeutics - Recent Pipeline Updates, H1 2016 86
Burns - Dormant Projects, H1 2016 90
Burns - Dormant Projects (Contd..1), H1 2016 91
Burns - Dormant Projects (Contd..2), H1 2016 92
Burns - Discontinued Products, H1 2016 93

List of Figures
Number of Products under Development for Burns, H1 2016 11
Number of Products under Development for Burns - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 39
Number of Products by Top 10 Targets, H1 2016 41
Number of Products by Stage and Top 10 Targets, H1 2016 41
Number of Products by Top 10 Mechanism of Actions, H1 2016 43
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 43
Number of Products by Routes of Administration, H1 2016 45
Number of Products by Stage and Routes of Administration, H1 2016 45
Number of Products by Top 10 Molecule Types, H1 2016 47
Number of Products by Stage and Top 10 Molecule Types, H1 2016 47

Companies Mentioned

Adocia
AlgiPharma AS
Amarantus Bioscience Holdings, Inc.
American Gene Technologies International Inc.
Biogenomics Limited
CytoTools AG
Destiny Pharma Limited
HanAll Biopharma Co., Ltd.
Kuros Biosciences AG
Madam Therapeutics B.V.
MediWound Ltd.
Novartis AG
Phosphagenics Limited
Se-cure Pharmaceuticals Ltd.
Stratatech Corporation
USV Limited


LICENSE TYPE